UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
November 13, 2018
CANCER
GENETICS, INC.
(Exact
Name of Registrant as Specified in its Charter)
Delaware
|
|
001-35817
|
|
04-3462475
|
(State
or Other
|
|
(Commission
|
|
(IRS
Employer
|
Jurisdiction
of Incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
201
Route 17 North 2nd Floor, Rutherford, New Jersey 07070
(Address
of Principal Executive Offices) (Zip Code)
Registrant’s
telephone number, including area code
(201) 528-9200
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
[X]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined by Rule 405 of the Securities Act of 1933 (17 §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]
Item
3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On
November 13, 2018, Cancer Genetics, Inc. (the “Company”) received a written notice from the Listing Qualifications
department of The Nasdaq Stock Market (the “Notice”) indicating that the Company is not in compliance with the $1.00
Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.
The
Nasdaq Listing Rules require listed securities to maintain a minimum bid price of $1.00 per share, and, based upon the closing
bid price for the last 30 consecutive business days, the Company no longer meets this requirement. The Notice indicated that the
Company will be provided 180 calendar days, or until May 13, 2019, in which to regain compliance. If at any time during this period
the bid price of the Company’s common stock closes at or above $1.00 per share for a minimum of ten consecutive business
days, the Nasdaq Staff will provide the Company with a written confirmation of compliance and the matter will be closed.
In
the event the Company does not regain compliance with Rule 5550(a)(2) by May 13, 2019, the Company may be eligible for additional
time within which to regain compliance. To qualify, the Company would be required to (i) meet the applicable market value of publicly
held shares requirement for continued listing and all other applicable requirements for initial listing on the Nasdaq Capital
Market (except for the bid price requirement) based on the Company’s most recent public filings and market information and
(ii) notify Nasdaq of its intent to cure this deficiency during the second compliance period by effecting a reverse stock split,
if necessary. If the Company meets these requirements, the Nasdaq Staff will inform the Company that it has been granted an additional
180 calendar days within which to regain compliance. However, if it appears to the Nasdaq Staff that the Company will not be able
to cure the deficiency, or if the Company is otherwise not eligible for such relief, the Nasdaq Staff will provide the Company
with written notification that its securities are subject to delisting from The Nasdaq Capital Market. At that time, the Company
may appeal the delisting determination to a Hearings Panel.
The
Company intends to monitor its bid price per share for the foreseeable future and may consider submitting for approval by its
stockholders a proposal to grant discretionary authority to the board of directors to amend the Company’s certificate of
incorporation to effect a reverse split of its outstanding shares of common stock within an appropriate range, with the exact
reverse split ratio to be decided and publicly announced by the board of directors prior to the effective time of the amendment
to the Company’s certificate of incorporation. Even if the Company chooses to pursue such an amendment, there can be no
assurance that the stockholders would approve such a reverse stock split or that the Company could maintain compliance with the
minimum bid price requirement after such a reverse stock split.
Forward-Looking
Statements
This
report contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements typically
are identified by use of terms such as “may,” “will,” “should,” “plan,” “expect,”
“anticipate,” “estimate” and similar words, and the opposites of such words, although some forward-looking
statements are expressed differently. Forward-looking statements involve known and unknown risks and uncertainties that exist
in the Registrant’s operations and business environment, which may be beyond the Registrant’s control, and which may
cause actual results, performance or achievements to be materially different from future results, performance or achievements
expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements
that could be forward- looking statements. For example, forward-looking statements include, without limitation: statements regarding
prospects for additional customers; market forecasts; projections of earnings, revenues, synergies, accretion or other financial
information; and plans, strategies and objectives of management for future operations. The risks and uncertainties referred to
above include, but are not limited to, risks detailed from time to time in the Registrant’s filings with the Securities
and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2017 and Quarterly Report on
Form 10-Q for the quarter ended June 30, 2018. These risks could cause actual results to differ materially from those expressed
in any forward- looking statements made by, or on behalf of, the Registrant. Forward-looking statements represent the judgment
of management of the Registrant regarding future events. Although the Registrant believes that the expectations reflected in such
forward-looking statements are reasonable at the time that they are made, the Registrant can give no assurance that such expectations
will prove to be correct. Unless otherwise required by applicable law, the Registrant assumes no obligation to update any forward-looking
statements, and expressly disclaims any obligation to do so, whether as a result of new information, future events or otherwise.
Additional
Information and Where to Find It
In
connection with the proposed transaction pursuant to the terms of the Agreement and Plan of Merger and Reorganization, dated as
of September 18, 2018, by and among Cancer Genetics, Inc., Wogolos, Ltd.. and NovellusDx , Ltd., Cancer Genetics intends to file
relevant materials with the Securities and Exchange Commission, or the SEC, including a registration statement that will contain
a proxy statement and prospectus. Investors and shareholders will be able to obtain free copies of the proxy statement, prospectus
and other documents filed by Cancer Genetics with the SEC (when they become available) through the website maintained by the SEC
at
www.sec.gov
. In addition, Cancer Genetics and NovellusDx investors and shareholders will be able to obtain free copies
of the proxy statement, prospectus and other documents filed by Cancer Genetics with the SEC by contacting Cancer Genetics, Inc.,
201 Route 17 North, 2
nd
Floor, Rutherford, New Jersey 07070, Attention: Corporate Secretary. Investors and stockholders
are urged to read the proxy statement, prospectus and the other relevant materials when they become available before making any
voting or investment decision with respect to the merger.
Participants
in the Solicitation
Cancer
Genetics and NovellusDx, and each of their respective directors and executive officers and certain of their other members of management
and employees, may be deemed to be participants in the solicitation of proxies in connection with the merger. Information about
Cancer Genetics’ directors and executive officers is included in Cancer Genetics’ Annual Report on Form 10-K for the
year ended December 31, 2017, filed with the SEC on April 2, 2018, and the Form 10-K/A filed with the SEC on April 30, 2018. Additional
information regarding these persons and their interests in the merger will be included in the proxy statement relating to the
merger when it is filed with the SEC. These documents can be obtained free of charge from the sources indicated above. This communication
is not intended to and does not constitute the solicitation of any vote in any jurisdiction pursuant to the merger or otherwise,
nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
CANCER
GENETICS, INC.
|
|
|
|
|
By:
|
/s/
John A. Roberts
|
|
Name:
|
John
A. Roberts
|
|
Title:
|
President
and Chief Executive Officer
|
|
|
|
Date:
November 16, 2018
|
|
|
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Oct 2023 to Oct 2024